The Editor's Roundtable: Hypertriglyceridemia

      Dr. Friedewald has no conflicts to disclose. Dr Ballantyne has received research grants and honoraria from Amarin Pharma, Inc. and has also received research grants and served as a consultant and speaker for numerous other pharmaceutical companies. Dr. Bays has received research grants and served as an adviser to Amarin Pharma Inc. and has also received research grants and served as a consultant and speaker for numerous other pharmaceutical companies. Dr. Jones is a consultant for Atherotech, Birmingham, Alabama; Merck, Whitehouse Station, New Jersey; Amarin; and Amgen, Thousand Oaks, California and is the Chief Science Officer for the National Lipid Association.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Miller M.
        • Stone N.
        • Ballantyne C.
        • Bittner V.
        • Criqui M.H.
        • Ginsberg H.N.
        • Goldberg A.C.
        • Howard W.J.
        • Jacobson M.S.
        • Kris-Etherton P.M.
        • Lennie M.
        • Mazzone T.
        • Pennathur S.
        Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 2292-2333
        • Bays H.E.
        Adiposopathy. Is “sick fat” a cardiovascular disease?.
        J Am Coll Cardiol. 2011; 57: 2461-2473
        • Bays H.E.
        • Gonzalez-Campoy J.M.
        • Bray G.A.
        • Kitabchi A.E.
        • Bergman D.A.
        • Schorr A.B.
        • Rodbard H.W.
        • Henry R.R.
        Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
        Expert Rev Cardiovasc Ther. 2008; 6: 343-368
      1. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins Textbook of Dyslipidemia. 530 Walnut Street Philadelpha PA.

        • Bays H.E.
        “Sick fat,” metabolic disease, and atherosclerosis.
        Am J Med. 2009; 122: S26-S37
        • Bays H.B.C.
        Adiposopathy: why do adiposity and obesity cause metabolic disease?.
        Future Lipidol. 2006; 1: 389-420
        • Maki K.C.
        • Bays H.E.
        • Dicklin M.R.
        Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence.
        J Clin Lipidol. 2012; 6: 413-426
        • Bays H.E.
        • Toth P.P.
        • Kris-Etherton P.M.
        • Abate N.
        • Aronne L.J.
        • Brown W.V.
        • Gonzalez-Campoy J.M.
        • Jones S.R.
        • Kumar R.
        • La Forge R.
        • Samuel V.T.
        Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
        J Clin Lipidol. 2013; 7: 304-383
        • Yokoyama M.
        • Origasa H.
        • Matsuzaki M.
        • Matsuzawa Y.
        • Saito Y.
        • Ishikawa Y.
        • Oikawa S.
        • Sasaki J.
        • Hishida H.
        • Itakura H.
        • Kita T.
        • Kitabatake A.
        • Nakaya N.
        • Sakata T.
        • Shimada K.
        • Shirato K.
        • Japan EPA lipid intervention study (JELIS) Investigators
        Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
        Lancet. 2007; 369: 1090-1098
        • Bays H.E.
        • Ballantyne C.M.
        • Kastelein J.J.
        • Isaacsohn J.L.
        • Braeckman R.A.
        • Paresh N.
        • Soni P.N.
        Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial).
        Am J Cardiol. 2011; 108: 682-690
        • Ballantyne C.M.
        • Bays H.E.
        • Kastelein J.J.
        • Stein E.
        • Isaacsohn J.L.
        • Braeckman R.A.
        • Soni P.N.
        Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR Study).
        Am J Cardiol. 2012; 110: 984-992
        • Bays H.E.
        • Ballantyne C.M.
        • Braeckman R.A.
        • Stirtan W.G.
        • Soni P.N.
        Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
        Am J Cardiovasc Drugs. 2013; 13: 37-46
      2. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Accessed on 7-25-13.

        • The AIM-HIGH Investigators
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • HPS2-THRIVE Collaborative Group
        HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
        Eur Heart J. 2013; 34: 1279-1291
        • The ACCORD Study Group
        Long-term effects of intensive glucose lowering on cardiovascular outcomes.
        N Engl J Med. 2011; 364: 818-828
        • Friedewald V.E.
        • Ballantyne C.M.
        • Davidson M.H.
        • Guyton J.R.
        • Roberts W.C.
        The Editor's Roundtable: lipid management beyond statins—reducing residual cardiovascular risk.
        Am J Cardiol. 2008; 102: 559-567